Framing Angle (from Research)
Eniola should lean hard into the Evariste precedent: Servier has already awarded its Golden Ticket to a computational oncology TechBio (Evariste), establishing that mathematical modelling and AI drug discovery belongs in SPartners. Her angle is that ESM-2 delta-embeddings solve the exact mutation-coverage gap that Servier's oncology and cancer-drug-resistance pipeline faces — 100% of clinically observed mutations vs. 17.6% for the structure-limited tools Servier's researchers currently rely on. The Servier pilot is not hypothetical: the application should state explicitly that the venture is already in dialogue with Servier colleagues at Paris-Saclay (via the SEMIA/Quest for Health pipeline) and that incubator residency would accelerate the de-risking of that pilot conversation within the 12-month ESM-2 fine-tuning roadmap. On infrastructure, she should reframe from 'I need wet labs' to 'I need the 2,000 Servier researcher network as validation collaborators and the BioLabs global investor network as my Series A pipeline' — this is an honest and compelling use case that reviewers can score as strong ecosystem fit even without bench usage.
Full Research →
The application materials are saved at .
Here is a summary of what was drafted:
ELEVATOR PITCH
Opens with the clinical problem (resistance mutation blindspot), states the 100% vs 17.6% coverage figure immediately, and names AUROC 0.634 on the Platinum benchmark in 50 words.
VENTURE DESCRIPTION
Four sub-sections covering the problem, the solution (ESM-2 delta-embeddings + ECFP4 + Random Forest), market context (oncology precision medicine, antiviral, AMR), and a full technology stack list. The SKEMPI fine-tuning roadmap to AUROC 0.70 is framed as the next concrete milestone.
MOTIVATION FOR SPARTNERS
Leads with the Evariste precedent as validation that SPartners already accepts computational oncology TechBio ventures. States the three specific things SPartners uniquely provides: structured Servier researcher access for wet lab validation, BioLabs investor introductions, and EIC/BPI institutional credibility. Makes clear the Servier pilot is active, not hypothetical.
FOUNDER PROFILE
Pharmacy-plus-ML framing, ORCID included, pre-incorporation status addressed honestly.
ROADMAP
Month-by-month milestones over 12 months from TRL 3-4 to pilot-validated, Series A-ready state.
COMPETITIVE LANDSCAPE
Names mCSM-lig, DynaMut, FoldX, Rosetta, DeepMut. Frames the sequence-only architecture as an architectural advantage, not a simplification.
WHAT THE VENTURE ASKS
Reframes away from lab needs toward the three assets SPartners actually controls: researcher access, investor network, institutional endorsement.
EDITOR NOTES flag five risks to address before submitting:
- Specificity of the Servier dialogue (get a date or document)
- Incorporation eligibility confirmation (may need French SAS before application)
- The AUROC comparison caveat (grouped vs non-grouped CV, prepare a technical clarification)
- Whether a video pitch is required on the VC4A form
- Whether physical Ile-de-France presence is a hard pre-application requirement